{"summary": "the MIRACLE trial is designed as a recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. the primary outcome is 90-day mortality. the primary analysis will follow the intention-to-treat principle. Supplementary information accompanies this paper at 10.1186/s13063-019-3846-x."}